HLA-A+ Tertiary Lymphoid Structures with Reactivated Tumor-Infiltrating Lymphocytes Are Associated with a Positive Immunotherapy Response in Esophageal Squamous Cell Carcinoma

In esophageal squamous cell carcinoma (ESCC), immune checkpoint blockade (ICB) therapy has achieved significant clinical benefits. However, the overall response rate to ICB treatment remains low. This study aims to identify biomarkers for ESCC response to ICB therapy and explore their potential clinical relevance. The authors of the paper come from...

Histone 3 Lysine 9 Acetylation-Specific Reprogramming Regulates Esophageal Squamous Cell Carcinoma Progression and Metastasis

The Mechanism of Action of Specific Reprogramming of Histone H3 Lysine 9 Acetylation (H3K9ac) in the Progression and Metastasis of Esophageal Squamous Cell Carcinoma (ESCC) Background Esophageal cancer is one of the most prevalent and invasive malignant tumors globally, causing over 500,000 cancer-related deaths annually, ranking sixth among cancer...

Romidepsin Exhibits Anti-Esophageal Squamous Cell Carcinoma Activity Through the DDIT4-mTORC1 Pathway

Romidepsin Exhibits Anti-Esophageal Squamous Cell Carcinoma Activity through DDIT4-mTORC1 Pathway Esophageal squamous cell carcinoma (ESCC) is one of the most common human malignancies globally, with high incidence and mortality rates. Given the limited current treatment options, there is an urgent need to develop new effective therapeutic drugs. I...